1. Search Result
Search Result
Results for "

Melanoma Metastasis

" in MedChemExpress (MCE) Product Catalog:

70

Inhibitors & Agonists

1

Peptides

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121524

    Microtubule/Tubulin Cancer
    DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research .
    DJ101
  • HY-121750

    Ras ROCK Cancer
    CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor . CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis .
    CCG-222740
  • HY-B0963

    5-Chloro-8-quinolinol

    Bacterial Fungal Parasite PPAR Infection Cancer
    Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ .
    Cloxiquine
  • HY-156483

    Others Cancer
    TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .
    TT-012
  • HY-119933

    RIP kinase Cancer
    RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .
    RIPK1-IN-7
  • HY-112052

    Endogenous Metabolite Cancer
    Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of L-asparagine synthetase from Leukemia 5178Y/AR (Ki= 0.0023 M) and mouse pancreas (Ki= 0.0015 M) in vitro. Aminomalonic acid is a potential biomarker to discriminate between different stages of melanoma metastasis .
    Aminomalonic acid
  • HY-156247

    NF-κB MMP Cancer
    IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis [1]
    IVMT-Rx-3
  • HY-124875

    HIF inhibitor 64B

    HIF/HIF Prolyl-Hydroxylase Neurological Disease
    Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the hypoxia-induced factor (HIF). Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma mouse model .
    Arylsulfonamide 64B
  • HY-120241

    K 251-1

    Phosphodiesterase (PDE) Cancer
    Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
    Reticulol
  • HY-119261

    Antibiotic Cancer
    Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .
    Ruboxyl
  • HY-B0963R

    Bacterial Fungal Parasite PPAR Infection Cancer
    Cloxiquine (Standard) is the analytical standard of Cloxiquine. This product is intended for research and analytical applications. Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ .
    Cloxiquine (Standard)
  • HY-139061

    LPL Receptor ROCK Cancer
    Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .
    Palmitoyl 3-carbacyclic phosphatidic acid
  • HY-150158

    Toll-like Receptor (TLR) Cancer
    TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research .
    TMX-201
  • HY-117231

    Others Cancer
    RM 06 is an immunomodulator with a peptidyl hypoxanthine structure that significantly reduces the number of lung metastases of B16 melanoma cells in mice after lethal irradiation and bone marrow reconstitution by stimulating the activity of natural killer (NK) cells .
    RM 06
  • HY-157092B

    ICMT Cancer
    (R)-ICMT-IN-3 (compound ent 2-27) is an inhibitor of ICMT (IC50=0.01 μM) .
    (R)-ICMT-IN-3
  • HY-157092A

    ICMT Cancer
    (S)-ICMT-IN-3 (compound ent 1-27) is an inhibitor of ICMT (IC50=0.23 μM) .
    (S)-ICMT-IN-3
  • HY-156500

    ICMT Cancer
    ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC50=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
    ICMT-IN-1
  • HY-157097

    ICMT Cancer
    ICMT-IN-10 (compound 32) is an inhibitor of ICMT (IC50=0.184 μM) .
    ICMT-IN-10
  • HY-155421

    ICMT Cancer
    ICMT-IN-11 (compound 48) is an inhibitor of ICMT (IC50=0.031 μM) .
    ICMT-IN-11
  • HY-149706

    ICMT Cancer
    ICMT-IN-12 (compound 78) is an inhibitor of ICMT (IC50=0.42 μM) .
    ICMT-IN-12
  • HY-155422

    ICMT Cancer
    ICMT-IN-13 (compound 49) is an inhibitor of ICMT (IC50=0.47 μM) .
    ICMT-IN-13
  • HY-155423

    ICMT Cancer
    ICMT-IN-14 (compound 50) is an inhibitor of ICMT (IC50=0.025 μM) .
    ICMT-IN-14
  • HY-155424

    ICMT Cancer
    ICMT-IN-15 (compound 51) is an inhibitor of ICMT (IC50=0.032 μM) .
    ICMT-IN-15
  • HY-157098

    ICMT Cancer
    ICMT-IN-16 (compound 33) is an inhibitor of ICMT (IC50=0.131 μM) .
    ICMT-IN-16
  • HY-155425

    ICMT Cancer
    ICMT-IN-17 (compound 52) is an inhibitor of ICMT (IC50=0.38 μM) .
    ICMT-IN-17
  • HY-157099

    ICMT Cancer
    ICMT-IN-18 (compound 35) is an inhibitor of ICMT (IC50=0.066 μM) .
    ICMT-IN-18
  • HY-155426

    ICMT Cancer
    ICMT-IN-19 (compound 53) is an inhibitor of ICMT (IC50=0.026 μM) .
    ICMT-IN-19
  • HY-155418

    ICMT Cancer
    ICMT-IN-2 (compound 45) is an inhibitor of ICMT (IC50=0.168 μM) .
    ICMT-IN-2
  • HY-155427

    ICMT Cancer
    ICMT-IN-20 (compound 54) is an inhibitor of ICMT (IC50=0.682 μM) .
    ICMT-IN-20
  • HY-149707

    ICMT Cancer
    ICMT-IN-21 (compound 6ag) is an ICMT inhibitor (IC50=8.8 μM), a sulfonamide-modified farnesyl cysteine (SMFC). The farnesyl and carboxylic acid motifs of ICMT-IN-21 are important structures for inhibiting ICMT .
    ICMT-IN-21
  • HY-155428

    ICMT Cancer
    ICMT-IN-22 (compound 62) is an inhibitor of ICMT (IC50=0.63 μM) .
    ICMT-IN-22
  • HY-157100

    ICMT Cancer
    ICMT-IN-23 (compound 36) is an inhibitor of ICMT (IC50=0.123 μM) .
    ICMT-IN-23
  • HY-155429

    ICMT Cancer
    ICMT-IN-24 (compound 63) is an inhibitor of ICMT (IC50=0.19 μM) .
    ICMT-IN-24
  • HY-157101

    ICMT Cancer
    ICMT-IN-25 (compound 37) is an inhibitor of ICMT (IC50=0.025 μM) .
    ICMT-IN-25
  • HY-157102

    ICMT Cancer
    ICMT-IN-26 (compound 38) is an inhibitor of ICMT (IC50=0.36 μM) .
    ICMT-IN-26
  • HY-155430

    ICMT Cancer
    ICMT-IN-27 (compound 64) is an inhibitor of ICMT (IC50=0.1 μM) .
    ICMT-IN-27
  • HY-155431

    ICMT Cancer
    ICMT-IN-28 (compound 65) is an inhibitor of ICMT (IC50=0.008 μM) .
    ICMT-IN-28
  • HY-155432

    ICMT Cancer
    ICMT-IN-29 (compound 66) is an inhibitor of ICMT (IC50=0.019 μM) .
    ICMT-IN-29
  • HY-157092

    ICMT Cancer
    ICMT-IN-3 (compound 27) is an inhibitor of ICMT (IC50=0.015 μM) .
    ICMT-IN-3
  • HY-155433

    ICMT Cancer
    ICMT-IN-30 (compound 67) is an inhibitor of ICMT (IC50=0.27 μM) .
    ICMT-IN-30
  • HY-155434

    ICMT Cancer
    ICMT-IN-31 (compound 68) is an inhibitor of ICMT (IC50=0.0038 μM) .
    ICMT-IN-31
  • HY-155435

    ICMT Cancer
    ICMT-IN-32 (compound 70) is an inhibitor of ICMT (IC50=0.777 μM) .
    ICMT-IN-32
  • HY-155436

    ICMT Cancer
    ICMT-IN-33 (compound 73) is an inhibitor of ICMT (IC50=0.46 μM) .
    ICMT-IN-33
  • HY-157103

    ICMT Cancer
    ICMT-IN-34 (compound 39) is an inhibitor of ICMT (IC50=0.17 μM) .
    ICMT-IN-34
  • HY-149709

    ICMT Cancer
    ICMT-IN-35 (compound 10n) is a FTPA-triazole compound and ICMT inhibitor (IC50=0.8 μM). ICMT-IN-35 is taken up by mammalian cells and can prevent K-Ras membrane localization and induce K-Ras mislocalization. Furthermore, ICMT-IN-35 is selectively cytotoxic against ICMT +/+ MEF cells and has low micromolar activity (IC50=0.8 μM) against metastatic pancreatic cancer cell lines .
    ICMT-IN-35
  • HY-157104

    ICMT Cancer
    ICMT-IN-36 (compound 40) is an inhibitor of ICMT (IC50=0.181 μM) .
    ICMT-IN-36
  • HY-157105

    ICMT Cancer
    ICMT-IN-37 (compound 41) is an inhibitor of ICMT (IC50=0.308 μM) .
    ICMT-IN-37
  • HY-157106

    ICMT Cancer
    ICMT-IN-38 (compound 42) is an inhibitor of ICMT (IC50=0.049 μM) .
    ICMT-IN-38
  • HY-157107

    ICMT Cancer
    ICMT-IN-39 (compound 18) is an inhibitor of ICMT (IC50=0.031 μM) .
    ICMT-IN-39
  • HY-157094

    ICMT Cancer
    ICMT-IN-4 (compound 28) is an inhibitor of ICMT (IC50=0.27 μM) .
    ICMT-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: